Heron Therapeutics (HRTX) Q1 2026: IGNITE 2.0 Expands Targeted Accounts by 38%, Setting Up Recovery
Heron Therapeutics navigated acute weather-driven headwinds in Q1, but March’s rebound and expanded commercial initiatives position the company for a strong back half of 2026. The IGNITE 2.0 program increased targeted accounts by 38%, while clinical guideline endorsements and salesforce expansion signal momentum for core products. Management reaffirmed full-year guidance, emphasizing that temporary disruptions are not expected to derail the company’s multi-pronged growth strategy.
Summary
- IGNITE 2.0 Account Expansion: Broader distributor focus increases Zinrelief’s commercial reach and supports share gains.
- Clinical Guideline Tailwind: Aponvy’s inclusion in consensus guidelines elevates its adoption trajectory in perioperative care.
- Salesforce and Pipeline Investments: Upcoming team expansions and pre-filled syringe development underpin confidence in 2026 targets.
Business Overview
Heron Therapeutics develops and commercializes pharmaceutical products addressing acute care and oncology supportive care needs. Revenue is generated primarily from its portfolio of hospital-administered drugs, including Zinrelief (local anesthetic), Aponvy (antiemetic for postoperative nausea and vomiting), Sinvanti (chemotherapy-induced nausea and vomiting), and legacy product Sustol, now in wind down. The business is organized into acute care and oncology segments, each with distinct product drivers and market dynamics.
Performance Analysis
Q1 was marked by severe January weather and typical seasonal copay resets, resulting in a high single-digit sequential decline in surgical volumes and softer top-line results. Despite these headwinds, Heron’s acute care portfolio showed resilience: Zinrelief posted 27% growth and Aponvy grew over 50% year-over-year, with both products outpacing broader market trends. Oncology supportive care, led by Sinvanti, maintained a stable 25% market share despite increased competition and category volatility.
Gross margin compressed to 69% due to higher-cost inventory from a secondary Sinvanti supplier, a temporary impact expected to resolve over the next two quarters as the company returns to exclusive use of its primary supplier. Adjusted EBITDA was negative, but management emphasized this was a transient effect from both revenue softness and margin drag. March’s net revenue rebound above $15 million signals recovery, and management reaffirmed full-year sales and profitability guidance.
- Acute Care Outperformance: Zinrelief and Aponvy both grew demand units well above market rates, with Aponvy’s ordering accounts hitting an all-time high.
- Pricing Discipline Maintained: No material price concessions were made, preserving long-term franchise economics.
- Temporary Margin Pressure: Higher-cost Sinvanti batches drove margin compression, but normalization is expected by Q3-Q4.
Strategic programs and operational execution supported underlying demand, even as headline results were held back by macro factors outside management’s control.
Executive Commentary
"While the weather undoubtedly weighed on our Q1 results, it has not shaken our confidence in the year ahead. We fully expect the remaining deferred elective procedures to be rescheduled throughout the remainder of 2026, creating a meaningful tailwind as we progress through the year."
Craig Collard, Chief Executive Officer
"Disciplined cost management remains a hallmark of this team that our shareholders have come to rely on... Both factors are temporary, and we expect adjusted EBITDA to return to positive territory as we move through 2026."
Ira Duarte, Chief Financial Officer
Strategic Positioning
1. IGNITE 2.0 and Commercial Expansion
The IGNITE program, Heron’s incentive partnership with orthopedic distributors, expanded targeted accounts by 38% for 2026—from 2,261 to 3,109 accounts. This expansion increases concentrated distributor focus on high-probability Zinrelief adopters, leveraging the 111% unit growth seen in IGNITE 1.0 as a baseline for broader impact. Enhanced alignment between Heron and distribution partners now covers nearly 90% of focus accounts, maximizing commercial leverage.
2. Clinical Guideline Endorsements for Aponvy
Aponvy’s inclusion in the fifth consensus guidelines for postoperative nausea and vomiting (PONV) is a pivotal clinical endorsement, elevating its status as the only FDA-approved IV push NK1 antagonist. This designation, combined with a new permanent J-code for streamlined reimbursement, is expected to drive durable adoption as institutions update protocols and EMR order sets to reflect new standards of care.
3. Salesforce Expansion and Operational Scale-Up
Heron is expanding both its Zinrelief and dedicated Aponvy/Sinvanti sales teams in Q3 2026, targeting geographies where payer access, formulary placement, and distributor programs are fully aligned. This investment is designed to accelerate share-of-voice and penetration in high-opportunity markets, supporting both acute care and oncology franchises.
4. Pipeline and Product Innovation
The Zinrelief pre-filled syringe (PFS) program is fully funded and on track, with 12-month stability data expected in Q1 2027. This innovation aligns with hospital demand for ready-to-use systems, supporting workflow efficiency and potentially unlocking new institutional adoption curves.
5. Oncology Franchise Durability
Sinvanti’s stable 25% market share reflects strong customer retention and resilience in a volatile, competitive NK1 category. The Reignite program is driving new formulary wins in major teaching hospitals, with a $10 million annualized pipeline of new accounts expected to contribute meaningfully in 2026.
Key Considerations
This quarter’s results must be viewed through the lens of transitory macro disruptions and the company’s proactive response. Management’s focus on commercial execution, pricing discipline, and clinical advocacy positions Heron to capitalize on deferred demand and new growth levers as the year unfolds.
Key Considerations:
- IGNITE 2.0 Scaling: The expanded program increases Zinrelief’s exposure in high-potential accounts, supporting continued share gains in acute care.
- Guideline-Driven Adoption: Aponvy’s clinical endorsement and streamlined reimbursement lower barriers to institutional uptake.
- Salesforce Leverage: Mid-year field expansion is timed to coincide with improved payer access and distributor alignment, amplifying commercial impact.
- Gross Margin Recovery: Temporary inventory cost headwinds will abate as the company transitions fully to its primary Sinvanti supplier.
- Pipeline Visibility: The Zinrelief PFS aligns with market trends toward ready-to-use injectables, positioning Heron for future workflow-driven adoption.
Risks
Heron remains exposed to external shocks such as weather-driven surgical delays and broader healthcare utilization volatility. Competitive intensity in both acute care and oncology supportive care could pressure pricing or share, despite current stability. Temporary gross margin headwinds underscore the risk of supply chain dependencies, though management expects normalization by Q3. Regulatory changes or payer dynamics could also impact reimbursement or access, especially as the company executes its salesforce and product expansion plans.
Forward Outlook
For Q2 2026, Heron expects:
- Recovery in elective procedure volumes and net revenue momentum established in March to continue.
- Gross margin improvement as high-cost inventory is worked through.
For full-year 2026, management reaffirmed guidance:
- Net product sales of $173 to $183 million.
- Adjusted EBITDA of $10 to $20 million, reflecting a return to profitability.
Management cited deferred procedures, expanded commercial programs, and salesforce investments as key drivers for hitting targets:
- IGNITE 2.0 and Reignite programs underpin account expansion and new revenue streams.
- Salesforce growth and clinical endorsements are expected to accelerate adoption across both core franchises.
Takeaways
Heron’s Q1 was a test of operational resilience rather than underlying demand.
- IGNITE 2.0 Expansion: The 38% increase in targeted accounts for Zinrelief provides a structural lever for share gains as deferred procedures return.
- Guideline and Reimbursement Tailwinds: Aponvy’s clinical guideline inclusion and new J-code streamline adoption pathways, while Sinvanti’s market share durability reflects franchise stickiness.
- Execution Watchpoint: The pace and effectiveness of salesforce expansion and the rollout of the Zinrelief pre-filled syringe will be critical for sustaining momentum into 2027.
Conclusion
Heron Therapeutics absorbed a challenging Q1 but is positioned for a strong recovery, with commercial expansion, clinical endorsements, and operational investments supporting its reaffirmed 2026 guidance. Investors should watch for execution on salesforce growth and pipeline milestones as key indicators of durability and upside potential.
Industry Read-Through
This quarter’s acute care headwinds and subsequent March rebound mirror trends seen across the hospital and elective procedure landscape, reinforcing that weather and macro disruptions are transitory for well-positioned players. Heron’s success with targeted distributor programs, clinical advocacy, and pricing discipline offers a playbook for other specialty pharma companies seeking to drive durable adoption in competitive categories. The migration toward ready-to-use injectables and workflow-driven adoption is a broader theme likely to shape hospital purchasing and formulary decisions across the sector. Guideline-driven product elevation and payer alignment remain critical levers for commercial momentum in specialty therapeutics.